Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Presystemic extraction: mechanisms and consequences

D J Greenblatt1

  • 1Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Massachusetts.

Journal of Clinical Pharmacology
|July 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to diazepam in sons of alcoholics.

Alcoholism, clinical and experimental research·1992
Same author

Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone.

Brain research bulletin·1992
Same author

Mental illness, pharmacotherapy, and automobile operation: what is the risk?

Journal of clinical psychopharmacology·1992
Same author

Bioavailability studies of drugs with nonlinear pharmacokinetics: I. Tracer dose AUC varies directly with serum concentration.

Journal of clinical pharmacology·1992
Same author

Pharmacokinetics and preliminary observations of behavioral changes following administration of midazolam to dogs.

Journal of veterinary pharmacology and therapeutics·1992
Same author

Fluoxetine impairs clearance of alprazolam but not of clonazepam.

Clinical pharmacology and therapeutics·1992
Same journal

FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

Journal of clinical pharmacology·2026
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
Same journal

New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

Journal of clinical pharmacology·2026
Same journal

Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

Journal of clinical pharmacology·2026
Same journal

The Journal of Clinical Pharmacology: 65 Years of History.

Journal of clinical pharmacology·2026
Same journal

Decoupling CAR-T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi-Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model.

Journal of clinical pharmacology·2026
See all related articles

Many oral drugs have low systemic availability due to presystemic extraction, where the body metabolizes the drug before it enters circulation. This impacts drug levels but not how long it stays in the body.

Area of Science:

  • Pharmacokinetics
  • Drug Metabolism
  • Drug Absorption

Background:

  • Oral drug administration is common, but many drugs exhibit incomplete systemic availability.
  • This limitation is often due to poor absorption or significant presystemic extraction.
  • Presystemic extraction involves drug biotransformation in the gastrointestinal tract or liver before reaching systemic circulation.

Purpose of the Study:

  • To explain the pharmacokinetic implications of presystemic extraction on oral drug bioavailability.
  • To elucidate the mechanisms contributing to reduced systemic drug availability after oral dosing.

Main Methods:

  • Review of pharmacokinetic principles governing oral drug absorption and disposition.
  • Analysis of factors influencing presystemic drug metabolism in the gastrointestinal tract and liver.

Related Experiment Videos

  • Pharmacokinetic modeling to understand the relationship between clearance, bioavailability, and elimination half-life.

    • Main Results:

    • Presystemic extraction by gastrointestinal mucosa, enteric flora, or hepatic first-pass metabolism significantly reduces oral bioavailability.
    • For drugs with high presystemic extraction, impaired clearance results in elevated peak plasma concentrations and increased area under the concentration-time curve.
    • Elimination half-life remains largely unchanged despite alterations in drug clearance and systemic exposure.

    Conclusions:

    • Presystemic extraction is a critical determinant of oral drug bioavailability.
    • Understanding these metabolic pathways is essential for optimizing oral drug therapy.
    • Altered clearance due to presystemic metabolism affects drug exposure but not its intrinsic elimination rate.